Seattle Genetics went from ASH to the 2019 San Antonio Breast Cancer Symposium, where it shared detailed data from its pivotal tucatinib trial.
News
- SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
- SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months
The data, presented at the San Antonio Breast Cancer Symposium, come from 184 patients with advanced HER2-positive breast cancer who received ...
- Hispanic Chamber's Erika Gonzalez Wants to Keep Small Businesses Healthy
Dr. Erika Gonzalez joined the San Antonio Hispanic Chamber of Commerce in ... involved in the group's efforts related to health care and biosciences.
- Phoenix Biotechnology Announces Completion of Private Placement
SAN ANTONIO--(BUSINESS WIRE)--Phoenix Biotechnology, Inc. (“Phoenix” or the “Company” www.phoenixbiotechnology.com) today announced ...
- Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative ...
... Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium .... About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime ...